SCA
ADPT icon

Spearhead Capital Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Spearhead Capital Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12,539
Closed -$101K – 102
2022
Q2 		$101K Sell
12,539
-258
-2% -$2.27K 0.02% 178
2022
Q1 		$178K Buy
+12,797
New +$201K 0.02% 190

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Spearhead Capital Advisors's ADPT Position: Q3 2022 in Review

Spearhead Capital Advisors sold out of Adaptive Biotechnologies (ADPT) in Q3 2022, closing a stake of 12,539 shares — an estimated $101K sold.

Spearhead Capital Advisors first reported a position in ADPT in Q1 2022 and held it in 2 quarters. The position peaked at $178K in Q1 2022. 226 funds tracked by Wall St. Rank hold ADPT as of Q3 2022.

  • Spearhead Capital Advisors reported no remaining Adaptive Biotechnologies position as of Q3 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 12,539 Adaptive Biotechnologies shares in Q3 2022, an estimated $101K.
  • Spearhead Capital Advisors first reported a position in Adaptive Biotechnologies in Q1 2022 and held it in 2 quarters.
  • Spearhead Capital Advisors's Adaptive Biotechnologies position peaked at $178K in Q1 2022.
  • 226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2022.

Based on Spearhead Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.